Top Markets
#1 Pleasing Gold Pleasing Gold +377.04%
#2 Islamic Coin Islamic Coin +154.26%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +48.86%
#5 DogBull DogBull +35.12%
#6 ORDI ORDI +19.56%
#7 Nockchain Nockchain +19.12%
#8 Ergo Ergo +16.59%
#9 Merlin's Seal BTC Merlin's Seal BTC +15.89%
#10 rsERG rsERG +15.86%
Coin of the day
Pleasing Gold Pleasing Gold
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rang in Aktien #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aktienkurs
$1.48
Zuletzt synchronisiert: 2023-05-31
Marktkapitalisierung
$35.54M
Veränderung (1 Tag)
-5.73%
Veränderung (1 Jahr)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Kategorie

Healthcare
P/S-Verhältnis für TCR2 Therapeutics Inc. (TCRR)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von TCR2 Therapeutics Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für TCR2 Therapeutics Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH